Latest Breaking News On - தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம் - Page 1 : comparemela.com

111, Inc Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China

111, Inc Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Yu gangDonafenib tosylateWorld health organizationChina national medical products associationExchange commissionSuzhou zelgen biopharmaceutical co ltdInternational agency for research on cancerSecurities exchangeSuzhou zelgen biopharmaceuticals co ltdInternational agencyNational medical products associationGeneral managerPrimary liver cancerExecutive chairmanSecurities exchange actSecurities litigation reform act

RareStone Inc Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with and without cataplexy in China

RareStone Inc Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with and without cataplexy in China
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMelissa bradford klugRarestone incRarestone groupNational medical products associationPrnewswire rarestone incStone incCitrine medicineNew drug applicationChief business officerMedia contactஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்மெலிசா பிராட்போர்டு க்லக்தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம்

Labeling Cosmetics in China: New Regulatory Standards

Labeling Cosmetics in China: New Regulatory Standards
china-briefing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from china-briefing.com Daily Mail and Mail on Sunday newspapers.

Administration of cosmeticsAdministration of cosmetic labeling theChina national medical products associationNational medical products associationCosmetic labelingசீனா தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம்தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம்ஒப்பனை லேபிளிங்

China Finalizes Animal Test Exemptions, CSAR Requirements for Cosmetics

China Finalizes Animal Test Exemptions, CSAR Requirements for Cosmetics March 5, 2021 Contact Author Rachel Grabenhofer Close Sponsored For cosmetics, the Provisions for Management of Cosmetic Registration and Notification Dossiers; and For ingredients, the Provisions for Management of New Cosmetic Ingredient Registration and Notification Dossiers. Beginning on May 1, 2021, companies should begin to submit registration and notification dossiers in accordance with the requirements specified therein. ChemLinked, include: Information on the product name; Product formula; Product safety assessment documents. In addition, as noted, imported general cosmetics can be exempted from animal testing from May 1, 2021, under certain conditions (see below). The regulation further clarifies the information required for annual reports of general cosmetics, which includes:

United kingdomNational agency for the safety of medicinesUnited kingdom department of internationalChina national medical products associationHealth productsNational medical products associationCosmetic registrationNotification dossiersNew cosmetic ingredient registrationChina finalizes cosmetic supervisionNotification informationTechnical standardsIntegrated approachesTesting exemptionNational agencyUnited kingdom department

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers - Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine - Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine

United statesScience parkSouth africaNew havenUnited arab emiratesYale universitySouth africanDavid spiegelSosei heptaresArtizan biosciencesBristol myers squibbMaryellen mcquadeMedison pharmaRichard flavellMike beyerKorean ministry of food